 Timothy Ung
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroma, Acoustic | 5 | 2024 | 55 | 1.930 |
Why?
| | Brain Neoplasms | 13 | 2025 | 1331 | 1.700 |
Why?
| | Meningioma | 5 | 2022 | 88 | 1.390 |
Why?
| | Meningeal Neoplasms | 5 | 2022 | 95 | 1.390 |
Why?
| | Glioblastoma | 8 | 2019 | 354 | 1.270 |
Why?
| | Radiosurgery | 4 | 2023 | 399 | 0.940 |
Why?
| | Skull Base Neoplasms | 3 | 2022 | 30 | 0.900 |
Why?
| | Spinal Cord Neoplasms | 2 | 2023 | 41 | 0.880 |
Why?
| | Central Nervous System Cysts | 2 | 2025 | 13 | 0.820 |
Why?
| | Fluorescein | 4 | 2021 | 24 | 0.800 |
Why?
| | Neurosurgical Procedures | 6 | 2022 | 202 | 0.780 |
Why?
| | Ependymoma | 2 | 2023 | 176 | 0.760 |
Why?
| | Ear, Inner | 1 | 2023 | 51 | 0.750 |
Why?
| | Spinal Neoplasms | 1 | 2023 | 37 | 0.740 |
Why?
| | Psychosurgery | 1 | 2021 | 9 | 0.690 |
Why?
| | Third Ventricle | 2 | 2021 | 16 | 0.630 |
Why?
| | Astrocytoma | 2 | 2025 | 130 | 0.630 |
Why?
| | Scalp | 1 | 2020 | 38 | 0.630 |
Why?
| | Arteriovenous Malformations | 1 | 2020 | 33 | 0.630 |
Why?
| | Neuroendoscopy | 2 | 2020 | 24 | 0.610 |
Why?
| | Laser Therapy | 1 | 2021 | 144 | 0.590 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 140 | 0.580 |
Why?
| | Neurologic Examination | 1 | 2019 | 132 | 0.560 |
Why?
| | Robotic Surgical Procedures | 1 | 2021 | 185 | 0.560 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 140 | 0.550 |
Why?
| | Olfaction Disorders | 1 | 2019 | 70 | 0.540 |
Why?
| | Smell | 1 | 2019 | 126 | 0.530 |
Why?
| | Bleomycin | 1 | 2019 | 255 | 0.530 |
Why?
| | Biopsy | 3 | 2021 | 1082 | 0.510 |
Why?
| | Tectum Mesencephali | 1 | 2015 | 1 | 0.460 |
Why?
| | Ventriculostomy | 1 | 2015 | 24 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1150 | 0.400 |
Why?
| | Exosomes | 1 | 2014 | 104 | 0.390 |
Why?
| | Trigeminal Neuralgia | 2 | 2023 | 15 | 0.380 |
Why?
| | Retrospective Studies | 17 | 2024 | 17330 | 0.380 |
Why?
| | Treatment Outcome | 12 | 2024 | 11794 | 0.360 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 381 | 0.350 |
Why?
| | Preoperative Care | 1 | 2014 | 380 | 0.330 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.320 |
Why?
| | Proteome | 1 | 2014 | 513 | 0.300 |
Why?
| | Humans | 35 | 2025 | 145783 | 0.280 |
Why?
| | Craniotomy | 2 | 2019 | 84 | 0.250 |
Why?
| | Transcription Factors | 1 | 2014 | 1736 | 0.240 |
Why?
| | Facial Nerve | 2 | 2024 | 39 | 0.230 |
Why?
| | Quality of Life | 4 | 2022 | 3211 | 0.220 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 72 | 0.220 |
Why?
| | Audiometry, Pure-Tone | 1 | 2024 | 33 | 0.210 |
Why?
| | Neoplasms | 2 | 2022 | 2913 | 0.200 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2219 | 0.200 |
Why?
| | Speech Perception | 1 | 2024 | 91 | 0.190 |
Why?
| | Skull Base | 2 | 2021 | 55 | 0.180 |
Why?
| | Glioma | 2 | 2018 | 429 | 0.180 |
Why?
| | Edema | 1 | 2023 | 125 | 0.180 |
Why?
| | Spinal Cord | 2 | 2023 | 382 | 0.180 |
Why?
| | Male | 17 | 2025 | 73011 | 0.180 |
Why?
| | Hematoma, Subdural, Chronic | 1 | 2021 | 4 | 0.180 |
Why?
| | Postoperative Period | 2 | 2021 | 351 | 0.170 |
Why?
| | Cavernous Sinus | 1 | 2021 | 16 | 0.170 |
Why?
| | Corpus Callosum | 1 | 2021 | 72 | 0.170 |
Why?
| | Spine | 1 | 2023 | 182 | 0.170 |
Why?
| | Signal Transduction | 1 | 2014 | 5224 | 0.160 |
Why?
| | Neurosurgery | 1 | 2021 | 41 | 0.160 |
Why?
| | Female | 16 | 2025 | 79045 | 0.160 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2020 | 27 | 0.160 |
Why?
| | Middle Aged | 12 | 2025 | 36309 | 0.160 |
Why?
| | Adult | 11 | 2025 | 40881 | 0.150 |
Why?
| | Cerebral Arteries | 1 | 2020 | 59 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 3 | 2018 | 3916 | 0.150 |
Why?
| | Surgical Flaps | 1 | 2020 | 142 | 0.140 |
Why?
| | Face | 1 | 2020 | 175 | 0.140 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2016 | 74 | 0.140 |
Why?
| | Dacarbazine | 2 | 2016 | 100 | 0.140 |
Why?
| | Magnetic Resonance Angiography | 1 | 2020 | 251 | 0.140 |
Why?
| | Aged | 9 | 2025 | 26217 | 0.130 |
Why?
| | Embolization, Therapeutic | 1 | 2020 | 243 | 0.130 |
Why?
| | Education, Medical | 1 | 2020 | 276 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 222 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 2015 | 85 | 0.110 |
Why?
| | Endovascular Procedures | 1 | 2020 | 390 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 154 | 0.110 |
Why?
| | Tissue Distribution | 1 | 2015 | 335 | 0.110 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 289 | 0.110 |
Why?
| | Neoplasm Grading | 1 | 2015 | 311 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 697 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2023 | 8347 | 0.100 |
Why?
| | Extracellular Space | 1 | 2014 | 117 | 0.100 |
Why?
| | Microscopy | 1 | 2015 | 147 | 0.100 |
Why?
| | Mutation | 1 | 2025 | 4090 | 0.100 |
Why?
| | Ligation | 1 | 2014 | 91 | 0.100 |
Why?
| | Sella Turcica | 2 | 2025 | 17 | 0.100 |
Why?
| | Nose | 1 | 2014 | 67 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 673 | 0.090 |
Why?
| | Arteries | 1 | 2014 | 261 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1247 | 0.090 |
Why?
| | Adolescent | 2 | 2021 | 22577 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2865 | 0.080 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 447 | 0.080 |
Why?
| | Brain | 1 | 2023 | 2969 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1062 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 668 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1450 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1454 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1329 | 0.070 |
Why?
| | Proteomics | 1 | 2014 | 1188 | 0.070 |
Why?
| | Pain | 2 | 2023 | 791 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1482 | 0.060 |
Why?
| | Young Adult | 3 | 2025 | 14254 | 0.060 |
Why?
| | Salivary Glands | 1 | 2025 | 36 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2024 | 156 | 0.050 |
Why?
| | Trephining | 1 | 2021 | 1 | 0.040 |
Why?
| | Hydroxyapatites | 1 | 2021 | 16 | 0.040 |
Why?
| | Durapatite | 1 | 2021 | 37 | 0.040 |
Why?
| | Esthetics | 1 | 2021 | 50 | 0.040 |
Why?
| | Supratentorial Neoplasms | 1 | 2021 | 18 | 0.040 |
Why?
| | Journal Impact Factor | 1 | 2021 | 29 | 0.040 |
Why?
| | Bibliometrics | 1 | 2021 | 66 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2024 | 2977 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 221 | 0.040 |
Why?
| | Biomarkers | 2 | 2024 | 4302 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1139 | 0.030 |
Why?
| | Age Factors | 1 | 2025 | 3346 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2016 | 69 | 0.030 |
Why?
| | Margins of Excision | 1 | 2016 | 50 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2016 | 37 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 319 | 0.030 |
Why?
| | New York | 1 | 2015 | 128 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 325 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 85 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2015 | 288 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 404 | 0.030 |
Why?
| | Sex Distribution | 1 | 2015 | 388 | 0.030 |
Why?
| | Cohort Studies | 1 | 2025 | 6033 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 239 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 497 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1271 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Animals | 1 | 2015 | 38102 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2094 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1851 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2875 | 0.020 |
Why?
| | Child | 1 | 2022 | 22740 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10919 | 0.010 |
Why?
|
|
Ung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|